10x Genomics(TXG)
$62.05-0.85 (-1.35%)
TXG
10x Genomics financials statements
$62.05
At close:-0.85 (-1.35%)
Want to see TXG full AI Analyst Report?
10x Genomics (TXG) Ratios
1,308 Followers
10x Genomics Ratios
TXG's free cash flow for Q3 2026 was $14.86M. For the 2026 fiscal year, TXG's free cash flow was decreased by $-971.00K and operating cash flow was $15.83M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.46 | 4.97 | 4.69 | 4.85 | 6.77 |
| Quick Ratio | 4.09 | 4.26 | 4.11 | 4.23 | 6.23 |
| Cash Ratio | 3.09 | 2.92 | 2.83 | 1.68 | 5.32 |
| Solvency Ratio | 0.00 | -0.67 | -0.94 | -0.60 | -0.15 |
| Operating Cash Flow Ratio | 0.89 | 0.06 | -0.12 | -0.26 | -0.19 |
| Short-Term Operating Cash Flow Coverage | 12.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 439.41M | $ 375.88M | $ 371.92M | $ 411.80M | $ 546.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.09 | 0.10 | 0.09 | 0.08 |
| Debt-to-Equity Ratio | 0.20 | 0.12 | 0.13 | 0.12 | 0.10 |
| Debt-to-Capital Ratio | 0.17 | 0.10 | 0.11 | 0.11 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.29 | 1.30 | 1.28 | 1.25 |
| Debt Service Coverage Ratio | 0.02 | -34728.75 | -6407.48 | -278.40 | -33.61 |
| Interest Coverage Ratio | 0.00 | -48639.75 | -8040.27 | -352.82 | -61.10 |
| Debt to Market Cap | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.26 | 0.69 | 0.81 | 0.84 | 0.75 |
| Net Debt to EBITDA | -80.90 | 1.95 | 1.29 | 0.97 | 20.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 69.05% | 67.86% | 66.15% | 76.69% | 84.89% |
| EBIT Margin | -6.21% | -29.09% | -40.20% | -31.27% | -10.77% |
| EBITDA Margin | 0.61% | -21.94% | -33.15% | -24.88% | -5.01% |
| Operating Profit Margin | -17.25% | -31.85% | -42.88% | -32.52% | -10.79% |
| Pretax Profit Margin | -6.21% | -29.09% | -40.21% | -31.36% | -10.95% |
| Net Profit Margin | -6.77% | -29.90% | -41.23% | -32.15% | -11.87% |
| Continuous Operations Profit Margin | -6.77% | -29.90% | -41.23% | -32.15% | -11.87% |
| Net Income Per EBT | 109.11% | 102.77% | 102.55% | 102.49% | 108.39% |
| EBT Per EBIT | 35.99% | 91.33% | 93.76% | 96.44% | 101.52% |
| Return on Assets (ROA) | -4.18% | -19.88% | -26.43% | -16.13% | -5.71% |
| Return on Equity (ROE) | -5.47% | -25.72% | -34.42% | -20.60% | -7.12% |
| Return on Capital Employed (ROCE) | -12.49% | -24.29% | -31.66% | -18.70% | -5.82% |
| Return on Invested Capital (ROIC) | -12.34% | -24.01% | -31.23% | -18.52% | -5.79% |
| Return on Tangible Assets | -4.47% | -20.33% | -27.02% | -16.57% | -5.89% |
| Earnings Yield | -2.14% | -10.56% | -3.89% | -4.00% | -0.35% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.79 | 6.95 | 5.39 | 4.96 | 5.75 |
| Payables Turnover | 15.62 | 15.21 | 13.31 | 5.57 | 4.27 |
| Inventory Turnover | 3.53 | 2.36 | 2.84 | 1.47 | 1.24 |
| Fixed Asset Turnover | 2.24 | 1.97 | 1.79 | 1.44 | 2.13 |
| Asset Turnover | 0.62 | 0.66 | 0.64 | 0.50 | 0.48 |
| Working Capital Turnover Ratio | 1.29 | 1.31 | 1.27 | 0.90 | 0.76 |
| Cash Conversion Cycle | 126.85 | 183.03 | 168.78 | 255.66 | 273.38 |
| Days of Sales Outstanding | 46.84 | 52.51 | 67.74 | 73.66 | 63.44 |
| Days of Inventory Outstanding | 103.37 | 154.53 | 128.47 | 247.49 | 295.41 |
| Days of Payables Outstanding | 23.36 | 24.00 | 27.43 | 65.49 | 85.48 |
| Operating Cycle | 150.21 | 207.03 | 196.21 | 321.15 | 358.86 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.09 | 0.06 | -0.13 | -0.30 | -0.19 |
| Free Cash Flow Per Share | 1.04 | -0.05 | -0.55 | -1.45 | -1.11 |
| Dividend Paid and CapEx Coverage Ratio | 22.92 | 0.54 | -0.31 | -0.26 | -0.21 |
| Capital Expenditure Coverage Ratio | 22.92 | 0.54 | -0.31 | -0.26 | -0.21 |
| Operating Cash Flow Coverage Ratio | 0.86 | 0.08 | -0.16 | -0.35 | -0.26 |
| Operating Cash Flow to Sales Ratio | 0.21 | 0.01 | -0.02 | -0.07 | -0.04 |
| Free Cash Flow Yield | 6.39% | -0.33% | -0.99% | -3.98% | -0.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -46.60 | -9.45 | -25.70 | -24.99 | -282.32 |
| Price-to-Sales (P/S) Ratio | 3.17 | 2.83 | 10.60 | 8.03 | 33.51 |
| Price-to-Book (P/B) Ratio | 2.56 | 2.44 | 8.85 | 5.15 | 20.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 15.64 | -301.92 | -101.30 | -25.10 | -134.02 |
| Price-to-Operating Cash Flow Ratio | 14.96 | 259.56 | -431.44 | -123.46 | -769.07 |
| Price-to-Earnings Growth (PEG) Ratio | 0.61 | 0.31 | -0.52 | -0.14 | 3.13 |
| Enterprise Value Multiple | 439.61 | -10.96 | -30.68 | -31.32 | -647.77 |
| Enterprise Value | 1.72B | 1.47B | 6.29B | 4.02B | 15.93B |
| EV to EBITDA | 439.61 | -10.96 | -30.68 | -31.32 | -647.77 |
| EV to Sales | 2.67 | 2.40 | 10.17 | 7.79 | 32.48 |
| EV to Free Cash Flow | 13.21 | -256.28 | -97.23 | -24.35 | -129.90 |
| EV to Operating Cash Flow | 12.63 | 220.32 | -414.07 | -119.75 | -745.42 |
| Tangible Book Value Per Share | 5.85 | 5.73 | 6.14 | 6.84 | 7.14 |
| Shareholders’ Equity Per Share | 6.38 | 5.90 | 6.32 | 7.08 | 7.41 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.09 | -0.03 | -0.03 | -0.02 | -0.08 |
| Revenue Per Share | 5.15 | 5.07 | 5.28 | 4.54 | 4.44 |
| Net Income Per Share | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 |
| Tax Burden | 1.09 | 1.03 | 1.03 | 1.02 | 1.08 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.02 |
| Research & Development to Revenue | 0.37 | 0.43 | 0.44 | 0.51 | 0.43 |
| SG&A to Revenue | 0.49 | 0.56 | 0.00 | 0.57 | 0.52 |
| Stock-Based Compensation to Revenue | 0.17 | 0.23 | 0.27 | 0.26 | 0.20 |
| Income Quality | -3.12 | -0.04 | 0.06 | 0.20 | 0.37 |
Currency in USD
